Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea ; volume:8 ; number:12 ; day:22 ; month:11 ; year:2018 ; pages:1-10 ; date:12.2018
Blood cancer journal ; 8, Heft 12 (22.11.2018), 1-10, 12.2018
- Urheber
-
Pacilli, Annalisa
Rotunno, Giada
Mannarelli, Carmela
Fanelli, Tiziana
Pancrazzi, Alessandro
Contini, Elisa
Mannelli, Francesco
Gesullo, Francesca
Bartalucci, Niccolò
Fattori, Giuditta Corbizi
Paoli, Chiara
Vannucchi, Alessandro M.
Guglielmelli, Paola
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-018-0152-x
- URN
-
urn:nbn:de:101:1-2019010822553816970431
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:03 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pacilli, Annalisa
- Rotunno, Giada
- Mannarelli, Carmela
- Fanelli, Tiziana
- Pancrazzi, Alessandro
- Contini, Elisa
- Mannelli, Francesco
- Gesullo, Francesca
- Bartalucci, Niccolò
- Fattori, Giuditta Corbizi
- Paoli, Chiara
- Vannucchi, Alessandro M.
- Guglielmelli, Paola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Management of myelofibrosis after ruxolitinib failure
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Management of myelofibrosis after ruxolitinib failure
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Management of myelofibrosis after ruxolitinib failure
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Ruxolitinib-based combinations in the treatment of myelofibrosis: worth looking forward to
Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
Use of roxadustat (FG-4592) in ruxolitinib-treatment-related anemia of two myelofibrosis patients
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and Outcomes
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib